Editorial Acesso aberto Revisado por pares

The influence of antiretroviral therapy on clinical aspects of HIV-related lymphoma

2017; Future Medicine; Volume: 6; Issue: 2 Linguagem: Inglês

10.2217/ijh-2017-0017

ISSN

2045-1407

Autores

José‐Tomás Navarro, Josep‐María Ribera,

Tópico(s)

Chronic Lymphocytic Leukemia Research

Resumo

International Journal of Hematologic OncologyVol. 6, No. 2 EditorialThe influence of antiretroviral therapy on clinical aspects of HIV-related lymphomaJosé-Tomás Navarro & Josep-Maria RiberaJosé-Tomás Navarro*Author for correspondence: Tel.: +34 934 978 868; E-mail Address: jnavarro@iconcologia.net Catalan Institute of Oncology-Germans Trias i Pujol Hospital, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Spain & Josep-Maria Ribera Catalan Institute of Oncology-Germans Trias i Pujol Hospital, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, SpainPublished Online:17 Nov 2017https://doi.org/10.2217/ijh-2017-0017AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleReferences1 Salters KA, Cescon A, Zhang W et al. Cancer incidence among HIV-positive women in British Columbia, Canada: heightened risk of virus-related malignancies. HIV Med. 17, 188–195 (2016).Crossref, Medline, CAS, Google Scholar2 Vandenhende MA, Roussillon C, Henard S et al. Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000. PLoS ONE 17, e0129550 (2015).Google Scholar3 Achenbach CJ, Cole SR, Kitahata MM et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 25, 691–700 (2011).Crossref, Medline, Google Scholar4 Hleyhel M, Belot A, Bouvier AM et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin. Infect. Dis. 57, 1638–1647 (2013).Crossref, Medline, CAS, Google Scholar5 Yanik EL, Tamburro K, Eron JJ, Damania B, Napravnik S, Dittmer DP. Recent cancer trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011. Infect. Agent Cancer 8, 18 (2013).Crossref, Medline, Google Scholar6 Gopal S, Patel MR, Yanik EL et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J. Natl Cancer Inst. 105, 1221–1229 (2013).Crossref, Medline, Google Scholar7 Bohlius J, Schmidlin K, Boué F et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood 117, 6100–6108 (2011).Crossref, Medline, CAS, Google Scholar8 Olszewskia AJ, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS 30, 787–796 (2016).Crossref, Medline, Google Scholar9 Navarro JT, Ribera JM, Oriol A et al. International Prognostic Index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients. Haematologica 83, 508–513 (1998).Medline, CAS, Google Scholar10 Barta S, Samuel MS, Xue X et al. Changes in the influence of lymphoma and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann. Oncol. 26, 958–966 (2015).Crossref, Medline, CAS, Google Scholar11 Barta SK, Xue X, Wang D et al. A new prognostic score for AIDS-related lymphomas in the rituximab era. Haematologica 99, 1731–1737 (2014).Crossref, Medline, Google Scholar12 Castillo JJ, Bower M, Brühlmann J et al. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer 121, 423–431 (2015).Crossref, Medline, CAS, Google Scholar13 Barta SK, Xue X, Wang D et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood 122, 3251–3262 (2013).Crossref, Medline, CAS, Google Scholar14 Baptista MJ, García O, Morgades M et al. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. AIDS 29, 811–818 (2015).Crossref, Medline, CAS, Google Scholar15 Howlett C, Snedecor SJ, Landsburg DJ et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br. J. Haematol. 170, 504–514 (2015).Crossref, Medline, Google Scholar16 Montoto S, Wilson J, Shaw K et al. Excellent immunological recovery following CODOXM/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS 24, 851–856 (2010).Crossref, Medline, CAS, Google Scholar17 Xicoy B, Ribera JM, Müller M et al. Dose-intense chemotherapy including rituximab is highly effective but toxic in HIV-infected patients with Burkitt's lymphoma/leukemia: parallel study of 81 patients. Leuk. Lymphoma 55, 2341–2348 (2014).Crossref, Medline, CAS, Google Scholar18 Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood 125, 2323–2330 (2015).Crossref, Medline, CAS, Google Scholar19 Montoto S, Shaw K, Okosum J et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J. Clin. Oncol. 30, 4111–4116 (2012).Crossref, Medline, Google Scholar20 Sorigué M, García O, Tapia G et al. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. AIDS doi:10.1097/QAD.0000000000001487 (2017) (Epub ahead of print).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 6, No. 2 Follow us on social media for the latest updates Metrics Downloaded 19 times History Received 10 May 2017 Accepted 23 May 2017 Published online 17 November 2017 Published in print November 2017 Information© 2017 Future Medicine LtdFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download

Referência(s)